CoChat

Defining the Prevalence and Incidence of Androgen Deficiency in Aging Men: Where Are the Goal Posts?

Open access
McLachlan, Robert I., Allan, Carolyn A. · 2004 · The Journal of Clinical Endocrinology & Metabolism
Cited by 37

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

The physical and cognitive declines noted by men as they age have historically been regarded as an integral part of the normal aging process, yet have also long been the target of empirical therapies aimed at restoring youthful vigor. In recent years, there has been a great deal of medical, social, and commercial interest in whether a decline in serum testosterone (T) underscores some of these changes and would thus be amenable to T replacement therapy (TRT). Various terms have been popularized such as “andropause” or “partial androgen deficiency of the aging male,” yet there is no consensus on their definitions (1, 2). It is clear that total T levels decline by 1–2% per annum beginning at ages in the fourth decade, and consequently an increasing proportion of the aging male population has serum T levels below the reference range for healthy young men. For example, age-stratified prevalence data from the Baltimore Longitudinal Study of Aging showed that 19% of 60- to 69-yr-old men had total T levels below those of normal young men (3), raising the possibility that large numbers of men, simply by virtue of falling below an arbitrary threshold, are potential candidates for TRT. However, the nonspecific symptoms consistent with, but not diagnostic of, androgen deficiency (AD) that are prevalent in aging men may be partially or wholly due to comorbidities (4). Despite lack of evidence of benefit over risk (1), clinical practice has evolved rapidly in this area, fuelled by patient expectations of improved physical function and quality of life and by the availability of convenient forms of T (such as the hydroalcoholic gels), leading to a 29% increase in the prescription of TRT between the years 2001 and 2002 (1), mainly in 46- to 65-yr-old men. The diagnosis of AD demands a synthesis of both clinical features and serum T measures particularly in aging men, as neither is consistently reliable in isolation. With unambiguous clinical features in men with established testicular or pituitary pathology and a serum T level less than 200–250 ng/dl (6.9–8.7 nm), the diagnosis of AD and the merits of treatment are well grounded. In clinical practice, however, most men present with relatively nonspecific symptoms, have confounding medical diagnoses (obesity, chronic illness), and maintain serum T levels in the low-normal range. Moreover, biochemical evaluation is complicated by interindividual variability in normal serum T (extending over a 4-fold range), poor assay performance characteristics, and inappropriate reference ranges (see below). Although attractive and certainly convenient, use of single-value cut-offs to decide clinical treatment is best described as “endonumerology!” The article by Araujo et al. (5) in this issue, for the first time, attempts to estimate the prevalence and incidence of AD in a prospective longitudinal study using operational diagnostic criteria based on clinical and biochemical parameters, reflecting the recommendation of the Second Annual Andropause Consensus group (2). The Massachusetts Male Aging Study (MMAS) data set includes eight of the 12 clinical features proposed by the consensus group, along with serum total T (determined by a robust assay method) and calculated free T values. Their data are a considerable advance on prior studies reporting biochemical thresholds alone and provide a prototype for developing a more rational algorithm for the diagnosis of AD and for identifying cohorts for interventional clinical research studies. However, the authors readily acknowledge that their data have limitations, particularly in regard to the definition of AD. For example, subjects needed three or more positive responses to the eight questions for the diagnosis of AD. Most of these variables were assessed on a 1–4 scale, but the thresholds for these subscales are not provided other than for lethargy and erectile dysfunction. For lethargy, if a subject answered “some or a little” to the question “I could not get going” (in the past week), a positive response was recorded, yet many eugonadal men could be expected to respond in this way. For libido, a response that sexual activity was considered only once daily was recorded as a positive symptom of AD. The authors acknowledge that their choice of the three positive responses threshold was arbitrary, stating that two would not have been enough and eight would have been unreasonably stringent. Herein lies the problem with symptom questionnaires: symptoms and signs suggestive of AD are nonspecific and readily accounted for by comorbidities. Lethargy, reduced concentration, sleep disturbance, irritability, and depressed mood may relate to physical illness (and side effects of treatment), obesity, and/or lack of physical exercise and other lifestyle issues (such as alcohol or drug abuse), relationship difficulties, and occupational or financial stresses. Even low libido, a classic feature of AD, is commonly related to such comorbidities. Finally, ere

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2004-2035

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 37

Metadata

Authors
McLachlan, R. I., & Allan, C. A.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2004-12
Volume
89
Issue
12
Pages
5916-5919
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2016664718
Cited by
37
References
9
FWCI
2.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.